文献(301-400)

301. Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis

of randomized control trials. Circ Heart Fail 2015; 8: 33-40. PMID: 25399909

302. Belardinelli R, Capestro F, Misiani A, et al. Moderate exercise training improves functional capacity, quality of life, and endothelium-

dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.

Eur J Cardiovasc Prev Rehabil 2006; 13: 818-825. PMID: 17001224

303. Patwala AY, Woods PR, Sharp L, et al. Maximizing patient benefit from cardiac resynchronization therapy with the addition of structured

exercise training: a randomized controlled study. J Am Coll Cardiol 2009; 53: 2332-2339. PMID: 19539142

304. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with

severe chronic pulmonary hypertension. Circulation 2006; 114: 1482- 1489. PMID: 16982941

305. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint

Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European

Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society

for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37:67-119. PMID: 26320113

306. Conraads VM, Beckers P, Vaes J, et al. Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic

heart failure. Eur Heart J 2004; 25: 1797-1805. PMID: 15474694

307. Beckers PJ, Denollet J, Possemiers NM, et al. Combined endurance- resistance training vs. endurance training in patients with chronic

heart failure: a prospective randomized study. Eur Heart J 2008;29: 1858-1866. PMID: 18515805

308. Feiereisen P, Delagardelle C, Vaillant M, et al. Is strength training the more efficient training modality in chronic heart failure? Med Sci

Sports Exerc 2007; 39: 1910-1917. PMID: 17986897

309. Jewiss D, Ostman C, Smart NA. The effect of resistance training on clinical outcomes in heart failure: A systematic review and meta-

analysis. Int J Cardiol 2016; 221: 674-681. PMID: 27423089

310. Vigorito C, Abreu A, Ambrosetti M, et al. Frailty and cardiac rehabilitation: A call to action from the EAPC Cardiac Rehabilitation

Section. Eur J Prev Cardiol 2017; 24: 577-590. PMID: 27940954

311. Wisløff U, Støylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training

in heart failure patients: a randomized study. Circulation 2007; 115:3086-3094. PMID: 17548726

312. Ellingsen Ø, Halle M, Conraads V, et al. SMARTEX Heart Failure Study (Study of Myocardial Recovery After Exercise Training in

Heart Failure) Group. High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction. Circulation

2017; 135: 839-849. PMID: 28082387

313. Demopoulos L, Yeh M, Gentilucci M, et al. Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise

training in patients with congestive heart failure. Circulation 1997; 95: 1764-1767. PMID: 9107160

314. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-

based cohort study. Lancet 2009; 373: 739-745. PMID: 19249635

315. Kotecha D, Flather MD, Altman DG, et al. Beta-Blockers in Heart Failure Collaborative Group. Heart Rate and Rhythm and the Benefit

of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol2017; 69: 2885-2896. PMID: 28467883

316. Prystowsky EN, Benson DW, Fuster V, et al. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals.

From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-1277.

PMID: 8653857

317. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999; 131:

688-695. PMID: 10577332

318. Mancini GB, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker,

and long-term success. Am Heart J 1982; 104: 617-621. PMID: 7113903

319. Fresco C, Proclemer A. Clinical challenge. II. Management of recent onset atrial fibrillation. PAFIT-2 Investigators. Eur Heart J 1996; 17

Suppl C: 41-47. PMID: 8809538

320. Nagai R, Kinugawa K, Inoue H, et al. J-Land Investigators. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter

and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J

2013; 77: 908-916. PMID: 23502991

321. Li SJ, Sartipy U, Lund LH, et al. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus

Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry. Circ Heart

Fail 2015; 8: 871-879. PMID: 26243796

322. Rawles JM. What is meant by a “controlled” ventricular rate in atrial fibrillation? Br Heart J 1990; 63: 157-161. PMID: 2183858

323. 日本循環器学会．心房細動治療（薬物）ガイドライン（2013年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf

324. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients

with heart failure? J Am Coll Cardiol 2003; 42: 1944-1951. PMID: 14662257

325. Fauchier L, Grimard C, Pierre B, et al. Comparison of beta blocker and digoxin alone and in combination for management of patients

with atrial fibrillation and heart failure. Am J Cardiol 2009; 103: 248- 254. PMID: 19121446

326. Shiga T, Wakaumi M, Imai T, et al. Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ

J 2002; 66: 600-604. PMID: 12074281

327. Flaker GC, Blackshear JL, McBride R, et al. Stroke Prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac

mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527-532. PMID: 1512329

328. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National

Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870. PMID:11401607

329. Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary

stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-2738. PMID: 20966417

330. Camm AJ, Kirchhof P, Lip GY, et al. European Heart Rhythm Association. Guidelines for the management of atrial fibrillation: the Task

Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429. PMID:

20802247

331. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation.

N Engl J Med 2013; 369: 2093-2104. PMID: 24251359

332. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with

atrial fibrillation. N Engl J Med 2011; 365: 981-992. PMID:21870978

333. Houston DS, Zarychanski R. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 2671; author reply

2674-2675. PMID: 20042760

334. Pearson S, Troughton R, Richards AM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 2334-2335;

author reply 2335. PMID: 22168653

335. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients

with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962. PMID: 24315724

336. Xiong Q, Lau YC, Senoo K, et al. Non-vitamin K antagonist oral anticoagulants(NOACs) in patients with concomitant atrial fibrillation

and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015; 17: 1192-1200. PMID: 26335355

337. Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical

heart valves. N Engl J Med 2013; 369: 1206-1214. PMID: 23991661

337a. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients

withatrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100. PMID: 20299623

338. Dewilde WJ, Oirbans T, Verheugt FW, et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral

anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;

381: 1107-1115. PMID: 23415013

339. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with

EACTS. Eur Heart J 2016; 37: 2893-2962. PMID: 27567408

340. Shiga T, Kasanuki H. Drug therapy for ventricular tachyarrhythmia in heart failure. Circ J 2007; 71 Suppl: A90-A96. PMID: 17587746

341. Katoh T, Mitamura H, Matsuda N, et al. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening

refractory ventricular tachyarrhythmias: post-marketing special investigation. Circ J 2005; 69: 1237-1243. PMID: 16195624

342. Itoh H, Crotti L, Aiba T, et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J 2016; 37:

1456-1464. PMID: 26715165

343. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77: 392-397. PMID:

3338130

344. Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable

cardioverter- defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008; 117: 462-469. PMID:

18172038

345. Hayashi M, Miyauchi Y, Murata H, et al. Urgent catheter ablation for sustained ventricular tachyarrhythmias in patients with acute heart

failure decompensation. Europace 2014; 16: 92-100. PMID: 23858022

346. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in

congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417-1424. PMID:

9371164

347. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. JCARE-GENERAL Investigators. Characteristics and outcomes of patients with

heart failure in general practices and hospitals. Circ J 2007; 71: 449- 454. PMID: 17384441

348. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J 2013; 77: 2209-2217. PMID: 23955345

349. Kajimoto K, Sato N, Takano T. investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Relation of left

ventricular ejection fraction and clinical features or co-morbidities to outcomes among patients hospitalized for acute heart failure

syndromes. Am J Cardiol 2015; 115: 334-340. PMID: 25476557

350. Shiba N, Watanabe J, Shinozaki T, et al. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction--

comparison with nonischemic cardiomyopathy. Circ J 2005; 69: 143-149. PMID: 15671603

351. Kajimoto K, Minami Y, Sato N, et al. Investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) Registry. Etiology

of Heart Failure and Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced Ejection

Fraction. Am J Cardiol 2016; 118: 1881-1887. PMID: 27720439

352. Ricci R, Coletta C, Ceci V, et al. RIMA Researchers. Effect of early treatment with captopril and metoprolol singly and together on

postinfarction left ventricular remodeling. Am Heart J 2001; 142: E5. PMID: 11579369

353. Califf RM, Lokhnygina Y, Velazquez EJ, et al. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction

with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Am J Cardiol 2009; 104:

151-157. PMID: 19576338

354. Fearon WF, Shah M, Ng M, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation

myocardial infarction. J Am Coll Cardiol 2008; 51: 560-565. PMID: 18237685

355. Lorell BH, Isoyama S, Grice WN, et al. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia

in isolated, blood-perfused rabbit hearts. Circ Res 1988; 63:457-467. PMID: 3396161

356. Isoyama S, Apstein CS, Wexler LF, et al. Acute decrease in left ventricular diastolic chamber distensibility during simulated angina in

isolated hearts. Circ Res 1987; 61: 925-933. PMID: 3677344

357. Slezak J, Tribulova N, Okruhlicova L, et al. Hibernating myocardium: pathophysiology, diagnosis, and treatment. Can J Physiol

Pharmacol 2009; 87: 252-265. PMID: 19370079

358. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and

metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised

controlled trial. Lancet 2003; 362: 7-13. PMID: 12853193

359. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor

dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;

94: 258-265. PMID: 8759064

360. Kitakaze M, Asanuma H, Funaya H, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically

increase coronary blood flow in canine ischemic myocardium: role of bradykinin. J Am Coll Cardiol 2002; 40: 162-166. PMID: 12103271

361. Elkayam U, Johnson JV, Shotan A, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with

chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation 1999; 99: 2652-2657. PMID: 10338458

362. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection

fraction. N Engl J Med 1985; 312: 1665-1671. PMID: 3873614

363. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina:

a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on

Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33: 2092-2197. PMID: 10362225

364. Marui A, Kimura T, Nishiwaki N, et al. CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Three-year outcomes after

percutaneous coronary intervention and coronary artery bypass grafting in patients with heart failure: from the CREDO-Kyoto

percutaneous coronary intervention/coronary artery bypass graft registry cohort-2†. Eur J Cardiothorac Surg 2015; 47: 316-321;

discussion 321. PMID: 24662243

365. 日本循環器学会．不整脈の非薬物治療ガイドライン（2011年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf

366. 日本循環器学会．弁膜疾患の非薬物治療に関するガイドライン（2012年改訂版）．

http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf

367. Michler RE, Smith PK, Parides MK, et al. CTSN. Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation.

N Engl J Med 2016; 374: 1932-1941. PMID: 27040451

368. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of

Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on

Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70: 252-289. PMID: 28315732

369. Koelling TM, Aaronson KD, Cody RJ, et al. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left

ventricular systolic dysfunction. Am Heart J 2002; 144: 524-529.PMID: 12228791

370. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease:

executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J

Am Coll Cardiol 2014; 63: 2438-2488. PMID: 24603192

371. Vahanian A, Alfieri O, Andreotti F, et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of

Cardiology (ESC). Guidelines on the management of valvular heartdisease (version 2012). Eur Heart J 2012; 33: 2451-2496. PMID:

22922415

372. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562. PMID:

8622246

373. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with

coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884- 893. PMID: 16785477

374. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients

with diabetes and coronary artery disease. JAMA 2010; 304:61-68. PMID: 20606150

375. Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus,

Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure:A Scientific Statement From the American Heart Association.

Circulation 2016; 134: e535-e578. PMID: 27799274

376. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with

heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA1995; 273: 1450-1456. PMID: 7654275

377. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled- release metoprolol on total mortality, hospitalizations, and

well-being in patients with heart failure: the Metoprolol CR/XL RandomizedIntervention Trial in congestive heart failure (MERIT-HF).

MERIT-HF Study Group. JAMA 2000; 283: 1295-1302. PMID:10714728

378. Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect

of carvedilol on the morbidity of patients with severe chronicheart failure: results of the carvedilol prospective randomized cumulative

survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199. PMID: 12390947

379. Packer M, O’Connor CM, Ghali JK, et al. Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine

on morbidity and mortality in severe chronic heart failure. N Engl JMed 1996; 335: 1107-1114. PMID: 8813041

380. Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted

therapies for heart failure phenotypes. Eur Heart J 2014; 35: 2797-2815.PMID: 25104786

381. Ferrari R, Böhm M, Cleland JG, et al. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail 2015;

17: 665-671. PMID: 26079097

382. Udelson JE. Heart failure with preserved ejection fraction. Circulation 2011; 124: e540-e543. PMID: 22105201

383. Choy CK, Rodgers JE, Nappi JM, et al. Type 2 diabetes mellitus and heart failure. Pharmacotherapy 2008; 28: 170-192. PMID: 18225964

384. Boyer JK, Thanigaraj S, Schechtman KB, et al. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients

with diabetes mellitus. Am J Cardiol 2004; 93: 870-875. PMID:15050491

385. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a

population-based study. J Am Coll Cardiol 2010; 55: 300-305. PMID:20117433

386. Miura M, Sakata Y, Miyata S, et al. CHART-2 Investigators. Prognostic Impact of Diabetes Mellitus in Chronic Heart Failure According to

Presence of Ischemic Heart Disease - With Special Reference to Nephropathy. Circ J 2015; 79: 1764-1772. PMID: 26004750

387. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin- converting enzyme inhibitors and beta-blockers in the management

of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am

Coll Cardiol 2003; 41: 1529-1538. PMID: 12742294

388. McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic

heart failure and reduced left-ventricular systolic function taking angiotensin- converting-enzyme inhibitors: the CHARM-Added trial.

Lancet 2003; 362: 767-771. PMID: 13678869

389. Haas SJ, Vos T, Gilbert RE, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes

mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146: 848-853. PMID: 14597934

390. Deedwania PC, Giles TD, Klibaner M, et al. MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients

with diabetes and chronic heart failure: experiences from MERIT- HF. Am Heart J 2005; 149: 159-167. PMID: 15660048

391. Fernandez HM, Leipzig RM. Spironolactone in patients with heart failure. N Engl J Med 2000; 342: 132; author reply 133-134. PMID:

10636750

392. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular

outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326. PMID: 23992601

393. Scirica BM, Braunwald E, Raz I, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes

mellitus: observations from the SAVOR-TIMI 53 randomized trial.Circulation 2014; 130: 1579-1588. PMID: 25189213

394. Krum H, Roecker EB, Mohacsi P, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects

of initiating carvedilol in patients with severe chronic heart failure:results from the COPERNICUS Study. JAMA 2003; 289: 712-718.

PMID: 12585949

395. Wali RK, Iyengar M, Beck GJ, et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-

analysis of randomized trials. Circ Heart Fail 2011; 4: 18-26. PMID: 21036889

396. Castagno D, Jhund PS, McMurray JJ, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an

analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 2010; 12: 607-616. PMID: 20354032

397. Tang CH, Wang CC, Chen TH, et al. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release

in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. J Am Heart Assoc 2016; 5: e002584. PMID: 26738790

398. Edner M, Benson L, Dahlström U, et al. Association between renin- angiotensin system antagonist use and mortality in heart failure

with severe renal insufficiency: a prospective propensity scorematchedcohort study. Eur Heart J 2015; 36: 2318-2326. PMID:26069212

399 日本腎臓学会．CKD診療ガイド2012．東京医学社 2012.

400. Vardeny O, Wu DH, Desai A, et al. RALES Investigators. Influence of baseline and worsening renal function on efficacy of spironolactone

in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012; 60:

2082-2089. PMID: 23083787